These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36737405)

  • 1. CDCA4 interacts with IGF2BP1 to regulate lung adenocarcinoma proliferation via the PI3K/AKT pathway.
    Feng S; Cao H; Sui Y; Shen Z; Wu J; Ma R; Feng J
    Thorac Cancer; 2023 Mar; 14(8):724-735. PubMed ID: 36737405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic zinc finger protein ZNF687 accelerates lung adenocarcinoma cell proliferation and tumor progression by activating the PI3K/AKT signaling pathway.
    Li M; Liu Z; Hou Z; Wang X; Shi H; Li Y; Xiao X; Tang Z; Yang J; Luo Y; Zhang M; Chen M
    Thorac Cancer; 2023 May; 14(14):1223-1238. PubMed ID: 36944484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
    Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLC39A5 promotes lung adenocarcinoma cell proliferation by activating PI3K/AKT signaling.
    Liu Z; Hu Z; Cai X; Liu S
    Pathol Res Pract; 2021 Aug; 224():153541. PubMed ID: 34252710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UHMK1 promotes lung adenocarcinoma oncogenesis by regulating the PI3K/AKT/mTOR signaling pathway.
    Li Y; Wang S; Jin K; Jin W; Si L; Zhang H; Tian H
    Thorac Cancer; 2023 Apr; 14(12):1077-1088. PubMed ID: 36919755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of cell division cycle associated 4 on the Wilm's tumor cells viability via AKT/mTOR signaling pathway.
    Li S; Qin C; Chen Y; Wei D; Tan Z; Meng J
    Ren Fail; 2021 Dec; 43(1):1470-1478. PubMed ID: 34723730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-485-5p Suppress the Malignant Characteristics of the Lung Adenocarcinoma via Targeting NADPH Quinone Oxidoreductase-1 to Inhibit the PI3K/Akt.
    Chen Y; Wu L; Bao M
    Mol Biotechnol; 2023 May; 65(5):794-806. PubMed ID: 36219369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA LINC00511 promotes COL1A1-mediated proliferation and metastasis by sponging miR-126-5p/miR-218-5p in lung adenocarcinoma.
    Wang Y; Mei X; Song W; Wang C; Qiu X
    BMC Pulm Med; 2022 Jul; 22(1):272. PubMed ID: 35842617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mex3a interacts with LAMA2 to promote lung adenocarcinoma metastasis via PI3K/AKT pathway.
    Liang J; Li H; Han J; Jiang J; Wang J; Li Y; Feng Z; Zhao R; Sun Z; Lv B; Tian H
    Cell Death Dis; 2020 Aug; 11(8):614. PubMed ID: 32792503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
    Han K; Zhang Y
    J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway.
    Zhu HE; Yin JY; Chen DX; He S; Chen H
    Cell Death Dis; 2019 Nov; 10(11):854. PubMed ID: 31699997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA (let-7b-5p)-targeted DARS2 regulates lung adenocarcinoma growth by PI3K/AKT signaling pathway.
    Xu Y; Chen X
    Oncol Res; 2024; 32(3):517-528. PubMed ID: 38361754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
    Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FHL2 promotes the aggressiveness of lung adenocarcinoma by inhibiting autophagy via activation of the PI3K/AKT/mTOR pathway.
    Wang S; Liu B; Su Y; Wang N; Dong P; Xu X; Huang L; Li S; Gu J; Qiu Y; Deng J; Lin Z; Zhou Y
    Thorac Cancer; 2024 Mar; 15(8):630-641. PubMed ID: 38323374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
    Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
    J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF2BP3 aggravates lung adenocarcinoma progression by modulation of PI3K/AKT signaling pathway.
    Chen X; Zhu X; Shen X; Liu Y; Fu W; Wang B
    Immunopharmacol Immunotoxicol; 2023 Jun; 45(3):370-377. PubMed ID: 36972188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLITRK6 promotes the progression of lung adenocarcinoma by regulating PI3K/AKT/mTOR signaling and Warburg effect.
    Yu F; Zhao X; Li M; Meng M
    Apoptosis; 2023 Aug; 28(7-8):1216-1225. PubMed ID: 37219677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RACGAP1 promotes lung cancer cell proliferation through the PI3K/AKT signaling pathway.
    Xu Z; Wu S; Tu J; Wang M; Liang W; Cheng J; Guan J; Xu J
    Sci Rep; 2024 Apr; 14(1):8694. PubMed ID: 38622149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PLEK2 activates the PI3K/AKT signaling pathway to drive lung adenocarcinoma progression by upregulating SPC25.
    Zhang W; Yu L; Xu C; Tang T; Cao J; Chen L; Pang X; Ren W
    Cell Biol Int; 2024 Sep; 48(9):1285-1300. PubMed ID: 38894536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FAM83B promotes the invasion of primary lung adenocarcinoma via PI3K/AKT/NF-κB pathway.
    Zhang J; Wang J; Yue K; Li P; Shen W; Qiao X; Wang Y; Wu X
    BMC Pulm Med; 2023 Jan; 23(1):32. PubMed ID: 36690987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.